The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial
Identificadores
Identificadores
Fecha de publicación
2014Título de revista
CLINICAL CANCER RESEARCH
Tipo de contenido
Artigo